Table 2 Ongoing Clinical trials of enasidenib in adult AML
From: Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
NCT Number | Phase | disease | Interventions | Status |
|---|---|---|---|---|
NCT03683433 | Phase 2 | R/R AML; | Enasidenib plus Azacitidine | Recruiting |
NCT03881735 | Phase 2 | R/R AML; | Enasidenib; | Not yet recruiting |
NCT03825796 | Phase 2 | R/R AML | Enasidenib plus CPX-351 | Recruiting |
NCT01915498 | Phase 1/2 | Advanced AML | enasidenib | Active, not recruiting |
NCT03013998 | Phase 1/2 | Previously Untreated AML | enasidenib | Recruiting |
NCT02632708 | Phase 1 | Newly Diagnosed AML | Enasidenib plus standard chemotherapy | Active,not recruiting |
NCT02677922 | Phase 1/2 | Newly Diagnosed AML | Enasidenib plus Azacitidine | Active,not recruiting |
NCT03839771 | Phase 3 | Newly Diagnosed AML; | AG-221 plus standard chemotherapy | Not yet recruiting |
NCT03515512 | Phase 1 | Post-HSCT AML | Enasidenib as maintenance therapy after HSCT | Recruiting |
NCT03728335 | Phase 1 | Post-HSCT AML | enasidenib as maintenance therapy after HSCT | Not yet recruiting |
NCT02577406 | Phase 3 | AML ≥60 years | AG-221 versus conventional care regimens | Recruiting |